WO1993020934A1 - Suspension aqueuse stable contenant des liposomes - Google Patents
Suspension aqueuse stable contenant des liposomes Download PDFInfo
- Publication number
- WO1993020934A1 WO1993020934A1 PCT/JP1992/000512 JP9200512W WO9320934A1 WO 1993020934 A1 WO1993020934 A1 WO 1993020934A1 JP 9200512 W JP9200512 W JP 9200512W WO 9320934 A1 WO9320934 A1 WO 9320934A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposome
- aqueous suspension
- suspension
- aqueous
- taurine
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract description 21
- 239000007900 aqueous suspension Substances 0.000 title abstract description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract description 22
- 229960003080 taurine Drugs 0.000 abstract description 11
- 239000002245 particle Substances 0.000 abstract description 9
- 229960000686 benzalkonium chloride Drugs 0.000 abstract description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract description 8
- 238000001556 precipitation Methods 0.000 abstract description 4
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 210000003712 lysosome Anatomy 0.000 abstract 1
- 230000001868 lysosomic effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical class CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- -1 dimyris toy Chemical compound 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940113478 lecithin 200 mg Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/0004—Preparation of sols
- B01J13/0021—Preparation of sols containing a solid organic phase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Definitions
- the present invention relates to a technique for stably storing liposomes even when liposomes are stored in the form of an aqueous suspension.
- Liposomes are small vesicles composed of lipid bilayer membranes, and are excellent in biocompatibility. Many attempts have been made to use it. However, ribosomes are aqueous suspensions, and colloids are often chemically unstable in this state, and ribosome particles aggregate and fuse with each other, precipitates are formed by crystallization of membrane components, and the particle size increases. And the loss of commercial value due to changes in potency and appearance, such as the occurrence of lyso-form, which is said to be hemolytic due to hydrolysis.
- An object of the present invention is to provide a stable aqueous liposome suspension which does not precipitate, aggregate, or change the particle size for 6 months even when stored at 40 ° C., and generates less lyso-form.
- the present invention is a liposome aqueous suspension characterized by adding taurine and benzalkonium chloride.
- the amount of taurine to be added is 0.5 to 5.0% by weight based on the total amount of the preparation, and a molar ratio of 1:13 to 1: 133 with respect to the membrane component of C liposome. 1.0 to 3.0% by weight (molar ratio of 1:27 to 1:80 to the ribosome membrane component).
- the addition amount of Shii-Dani Benzalkonium is 0.05 to 20 mol per mol of the liposome membrane component. — ⁇ _
- the aqueous liposome suspension of the present invention can be prepared, for example, as follows: a membrane component is dissolved in an organic solvent, and after distilling off the organic solvent, the resulting lipid membrane is washed with 0 taurine. And hydration with an aqueous solution containing benzalkonium, or hydrated with an aqueous solution of taurine, and then benzalkonium chloride may be added, but the method is not particularly limited to this && method.
- Iil Hydrogenated as self-membrane component fcg lecithin, hydrogenated egg yolk lecithin, dimyris toy, phosphatidylcholine, dihal .: mitoylsfospatidylcholine, distea ⁇ -ylphosphatidylcholine, etc. No film stabilizer is required, but cholesterol may be added.
- the amount of the membrane component to be used is usually 0.0005 to 0.025 parts by weight, preferably 0.001 to 0.008 parts by weight per one part by weight of water.o
- chloro-form cyclo-form, dichloromethane, and the like can be used as the organic solvent.
- ⁇ ⁇ of the liposomal water suspension it is desirable to adjust ⁇ ⁇ of the liposomal water suspension to near neutral ⁇ ( ⁇ ⁇ 6.0 to 7.0) with sodium hydroxide, potassium hydroxide or the like.
- the particle size distribution of the liposome may be controlled by using a membrane filter made of polycarbonate or a high-pressure injection type homogenizer as necessary.
- the aqueous ribosome suspension of the present invention may contain, if necessary, a preservative C, such as methyl parahydroxybenzoate, ethyl ethyl paraoxybenzoate, propyl paraoxybenzoate, and antihistamines (eg, diphenhydramine hydrochloride, isotipendyl hydrochloride, maleine). acid-chloro Hue leek Min, etc.), vitamins (e.g. vitamin ⁇ and its ester le, activated vitamin: B 2, vitamin B s, vitamin beta 12, such as vitamin ⁇ and S.
- a preservative C such as methyl parahydroxybenzoate, ethyl ethyl paraoxybenzoate, propyl paraoxybenzoate, and antihistamines (eg, diphenhydramine hydrochloride, isotipendyl hydrochloride, maleine). acid-chloro Hue leek Min, etc.), vitamins (e.g. vitamin ⁇ and its ester le,
- lidocaine lidocaine hydrochloride, procaine hydrochloride, dibuforce hydrochloride, etc.
- freshener for example, ⁇ -menthol, borneol, camphor, potato power oil, etc.
- polymer additive polyethylene glycol, polyvinyl alcohol) Alcohol, polyvinylpyrrolidone, hydroxyethyl cellulose, hydro Ki And the like, tonicity agents (eg, sodium chloride, chlorinated lime, etc.) may be added as long as the effects of the present invention are not impaired.
- the drug retained in the aqueous liposome suspension of the present invention is not particularly limited.
- the drug is dissolved in an aqueous solution containing taurine (and benzalkonium chloride), added to a lipid membrane, and hydrated.
- the drug and the membrane component are dissolved in a solvent such as porcine and the solvent is distilled off, and then hydrated with an aqueous solution containing taurine (and benzalkonium chloride). .
- An aqueous ribosomal suspension was prepared in the same manner as in Example 1 except that 200 mg of dipalmitoylphosphatidylcholine was used instead of 200 mg of dimyristylphosphatidylcholine as a membrane component.
- a liposomal aqueous suspension was prepared in the same manner as in Example 1, except that 200 mg of hydrogenated soybean lecithin was used instead of 200 mg of dimyristoylphosphatidylcholine as a membrane component. However, hydration and sizing were performed at 60-70 ° C.
- a liposome aqueous suspension was prepared in the same manner as in Example 3, except that m was used.
- a liposomal water suspension was prepared in the same manner as in Example 3, except that hydrogenated soybean lecithin 200 mg and cholesterol 50 m were used instead of hydrogenated soybean lecithin 200 mg as a membrane component.
- a ribosome aqueous suspension was prepared in the same manner as in Example 1 except that a 13 mM phosphoric acid and a 140 mM sodium chloride aqueous solution were used in place of the aqueous solution of taurine. '
- a liposome aqueous suspension was prepared in the same manner as in Example 1 except that benzalkonium chloride was not added.
- Test example 1 A liposome aqueous suspension was prepared in the same manner as in Example 1 except that benzalkonium chloride was not added.
- Example 1 The aqueous suspensions of ribosomes of Example 1, Control Example 1 and Reference Example 2 were placed in a transparent sample at 40 ° C. and 65 ° C. Stored in C, temporarily separate phosphatidylcholine by thin-layer chromatography, scrape off this part, and use the E. Gerlach and D. Deu-tiche ⁇ method [Biochemiche Zeitschrift T, Vol. 337 , Page 477 (1963)], and the content of phosphatidylcholine was measured, and the results are shown in Table 1. The lyso-form, a major decomposition product, was produced. Example 1 was less than Controls 1 and 2. Storage temperature () 65 40 Storage period (days) At start 5 20 40 140 Example 1 100 100.0 83.6 72.9 94.5
- Example 1 placed ribosome water suspension of Reference Example 1 and Reference Example 2 in ampoules, and stored in 40 e C, to observe the appearance change, the particle size was determined. Table 2 shows the results. In the aqueous liposome suspension of Example 1, no aggregation and precipitation of liposomes and no change in particle size were observed.However, in Comparative Examples 1 and 2, aggregation was larger than in Example 1. ⁇ Lots of sediment and large particle size. Second ⁇
- Particle size unit is n m
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92908351A EP0637463A4 (en) | 1990-07-26 | 1992-04-21 | STABLE, AQUEOUS LIPOSOME SUSPENSION. |
AU15488/92A AU672579B2 (en) | 1990-07-26 | 1992-04-21 | Stable aqueous suspension of liposome |
US08/318,750 US5565213A (en) | 1990-07-26 | 1992-04-21 | Stable liposome aqueous suspension |
KR1019940703704A KR950701248A (ko) | 1990-07-26 | 1992-04-21 | 안정한 리포좀 수현탁액 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19823690 | 1990-07-26 | ||
JP22376191A JP3218637B2 (ja) | 1990-07-26 | 1991-05-27 | 安定なリポソーム水懸濁液 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993020934A1 true WO1993020934A1 (fr) | 1993-10-28 |
Family
ID=26510853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/000512 WO1993020934A1 (fr) | 1990-07-26 | 1992-04-21 | Suspension aqueuse stable contenant des liposomes |
Country Status (7)
Country | Link |
---|---|
US (1) | US5565213A (ja) |
EP (1) | EP0637463A4 (ja) |
JP (1) | JP3218637B2 (ja) |
KR (1) | KR950701248A (ja) |
AU (1) | AU672579B2 (ja) |
CA (1) | CA2118487A1 (ja) |
WO (1) | WO1993020934A1 (ja) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945121A (en) * | 1994-12-19 | 1999-08-31 | Taisho Pharmaceutical Co., Ltd. | Liposome eye drops |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6592877B1 (en) * | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
DE69701152T2 (de) * | 1996-11-01 | 2000-09-28 | Coloplast A/S, Humlebaek | Ein blasenkatheter-set mit einem gebrauchsfertigem katheter |
US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US7087713B2 (en) * | 2000-02-25 | 2006-08-08 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
AU9221698A (en) * | 1997-09-04 | 1999-03-22 | Biozone Laboratories, Inc. | Oral liposomal delivery system |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
ATE338120T2 (de) | 1998-11-27 | 2006-09-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
US8143386B2 (en) * | 1999-04-07 | 2012-03-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
US6024986A (en) * | 1999-05-24 | 2000-02-15 | Ecolab Inc. | Method of protecting growing plants from the effects of plant pathogens |
US7311922B1 (en) * | 1999-10-07 | 2007-12-25 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
ES2389445T3 (es) | 2000-02-23 | 2012-10-26 | Glaxosmithkline Biologicals Sa | Compuestos novedosos |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
SI1542732T1 (sl) | 2000-06-20 | 2010-01-29 | Corixa Corp Csc The United Sta | Fuzijski proteini Mycobacterium tuberculosis |
AU2001273149A1 (en) | 2000-06-28 | 2002-01-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
JP2002222083A (ja) | 2001-01-29 | 2002-08-09 | Fujitsu Ltd | 事例蓄積装置および方法 |
CA2446788A1 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP2224012B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US7026465B2 (en) * | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
RU2389732C2 (ru) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Некоторые аминоалкилглюкозаминидфосфатные производные и их применение |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
CN1798769A (zh) | 2003-05-12 | 2006-07-05 | 内蒂穆恩公司 | 抗masp-2抗体 |
US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
WO2006031264A2 (en) | 2004-05-25 | 2006-03-23 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
HUE032349T2 (en) | 2004-06-10 | 2017-09-28 | Omeros Corp | Procedures for the treatment of conditions associated with MASP-2 dependent complement mediated activation |
ZA200700367B (en) | 2004-06-14 | 2008-07-30 | Zoser B Salama | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody |
DK1885746T3 (da) | 2005-02-08 | 2012-03-26 | Res Dev Foundation | Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs) |
UA97943C2 (ru) | 2005-03-31 | 2012-04-10 | ГлаксоСмитКлайн Байолоджикалз с.а. | Вакцина против инфекции chlamydia |
ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
DK2457926T3 (da) | 2005-04-29 | 2015-01-05 | Glaxosmithkline Biolog Sa | Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
WO2007062399A2 (en) | 2005-11-23 | 2007-05-31 | The Board Of Regents Of The University Of Texas System | Oncogenic ras-specific cytotoxic compound and methods of use thereof |
AU2007239095B2 (en) | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
WO2008061013A2 (en) * | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
EP2094731A2 (en) * | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
EP3492596A1 (en) | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
US20080319388A1 (en) * | 2007-06-21 | 2008-12-25 | David Slattery | Device delivery system with balloon-relative sheath positioning |
EP3061462B1 (en) | 2007-07-02 | 2019-02-27 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
ES2552858T3 (es) | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
EP2628486A3 (en) * | 2007-12-14 | 2013-10-30 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
JP4395537B2 (ja) * | 2008-04-09 | 2010-01-13 | 株式会社資生堂 | ベシクル及びそれを含む化粧料 |
US8753639B2 (en) | 2009-03-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | Compositions and methods for modulating the activity of complement regulatory proteins on target cells |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
ES2545794T3 (es) | 2009-08-28 | 2015-09-15 | Research Development Foundation | Análogos de urocortina 2 y usos de los mismos |
RU2600876C2 (ru) | 2009-10-16 | 2016-10-27 | Омерос Корпорейшен | Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента |
WO2011062460A2 (ko) | 2009-11-23 | 2011-05-26 | 주식회사 엘지화학 | 다공성 코팅층을 구비한 분리막의 제조방법, 이로부터 형성된 분리막 및 이를 구비한 전기화학소자 |
EP2512600A2 (en) | 2009-12-18 | 2012-10-24 | Amgen Inc. | Wise binding agents and epitopes |
MX2012008790A (es) | 2010-01-27 | 2012-08-17 | Glaxosmithkline Biolog Sa | Antigenos de tuberculosis modificados. |
WO2011133901A2 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
KR20190060881A (ko) | 2010-04-23 | 2019-06-03 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 레베르 선천성 흑내장-1(lca1)의 치료를 위한 재조합 아데노-관련된 바이러스-구아닐레이트 사이클라제 조성물 및 방법 |
EP2826860B1 (en) | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
LT2569436T (lt) | 2010-05-14 | 2018-03-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas |
EP2569010B1 (en) | 2010-05-14 | 2017-04-12 | Amgen, Inc | High concentration antibody formulations |
CN103649118A (zh) | 2011-03-01 | 2014-03-19 | 安进公司 | 双特异性结合剂 |
SG193610A1 (en) | 2011-03-25 | 2013-11-29 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP3287142B1 (en) | 2011-04-08 | 2021-08-04 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
EP2699680B1 (en) | 2011-04-21 | 2017-12-27 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
CA3131223C (en) | 2011-05-04 | 2024-01-30 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
CN103608030A (zh) | 2011-06-21 | 2014-02-26 | 昂科发克特公司 | 用于治疗和诊断癌症的组合物和方法 |
HUE039786T2 (hu) | 2011-08-04 | 2019-02-28 | Amgen Inc | Csonthiány-defektusok kezelési módszere |
KR20190120401A (ko) | 2011-12-28 | 2019-10-23 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
CN104203272A (zh) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | 复合抗原序列及疫苗 |
WO2013180834A2 (en) | 2012-04-06 | 2013-12-05 | Omeros Corporation | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
ES2864857T3 (es) | 2012-06-18 | 2021-10-14 | Omeros Corp | Composiciones y métodos para la inhibición de MASP-1 y/o MASP-2 y/o MASP-3 para el tratamiento de diversas enfermedades y trastornos |
EP2869844B2 (en) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
SG10201701063WA (en) | 2012-08-10 | 2017-04-27 | Taiho Pharmaceutical Co Ltd | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
EP3985024A1 (en) | 2013-02-01 | 2022-04-20 | Atara Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
CN105188710A (zh) | 2013-03-15 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 |
SG11201507287SA (en) | 2013-03-15 | 2015-10-29 | Univ California | Peptides having reduced toxicity that stimulate cholesterol efflux |
EP3057993B1 (en) | 2013-10-17 | 2020-08-12 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
EP3750907A3 (en) | 2014-03-18 | 2021-04-28 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
EP3200830B1 (en) | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
US10900059B2 (en) | 2014-10-14 | 2021-01-26 | Research Development Foundation | Methods for generating engineered enzymes |
BR112017007737A2 (pt) | 2014-10-21 | 2018-01-30 | Univ Massachusetts | variantes de aav recombinantes e usos das mesmas |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
CA2967468A1 (en) | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Reversir(商標)化合物 |
AU2016205208A1 (en) | 2015-01-09 | 2017-07-06 | Etubics Corporation | Methods and compositions for ebola virus vaccination |
EP3247333B1 (en) * | 2015-01-20 | 2021-07-21 | Tetraderm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
EP3285788A4 (en) | 2015-04-23 | 2018-12-05 | University of Massachusetts | Modulation of aav vector transgene expression |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
SG10202011469UA (en) | 2015-11-09 | 2020-12-30 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
EP3383418B1 (en) | 2015-12-04 | 2021-10-20 | Board of Regents, The University of Texas System | Slc45a2 peptides for immunotherapy |
CN108495652A (zh) | 2016-01-05 | 2018-09-04 | 莱斯特大学 | 用于抑制有需要的受试者的纤维化的方法 |
EP4094780A3 (en) | 2016-02-12 | 2023-02-08 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
ITUB20161016A1 (it) * | 2016-02-24 | 2017-08-24 | Emenem Srl | Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi |
AU2017228413A1 (en) | 2016-03-03 | 2018-08-23 | University Of Massachusetts | Closed-ended linear duplex DNA for non-viral gene transfer |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
JP6865767B2 (ja) | 2016-03-31 | 2021-04-28 | オメロス コーポレーション | 血管形成の阻害を必要とする対象において血管形成を阻害するための方法 |
ES2913073T3 (es) | 2016-04-29 | 2022-05-31 | Icahn School Med Mount Sinai | Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis |
JOP20170154B1 (ar) | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
EP3510161A4 (en) | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
KR20190075964A (ko) | 2016-10-13 | 2019-07-01 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
AU2018248304C1 (en) | 2017-04-05 | 2023-02-16 | University Of Massachusetts | Minigene therapy |
EP3641794A4 (en) | 2017-06-23 | 2021-03-24 | The Trustees of Columbia University in the City of New York | METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERENCE, INCLUDING ALZHEIMER'S DISEASE |
TWI818919B (zh) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法 |
WO2019183605A1 (en) | 2018-03-23 | 2019-09-26 | University Of Massachusetts | Gene therapeutics for treating bone disorders |
WO2019191534A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
CN113164625A (zh) | 2018-09-28 | 2021-07-23 | 哈佛大学的校长及成员们 | 用于基因表达的突变体反向四环素反式激活因子 |
AU2019347666A1 (en) | 2018-09-28 | 2021-03-25 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
EP3887522A1 (en) | 2018-11-29 | 2021-10-06 | University of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
CA3131023A1 (en) | 2019-02-22 | 2020-08-27 | Michael R. Volkert | Oxr1 gene therapy |
CA3137520A1 (en) | 2019-04-24 | 2020-10-29 | University Of Massachusetts | Aav capsid chimeric antigen receptors and uses thereof |
JP2022547305A (ja) | 2019-09-13 | 2022-11-11 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | Aav適合性ラミニン-リンカー重合タンパク質 |
JP2023504541A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
WO2021113682A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
BR112022016596A2 (pt) | 2020-02-21 | 2022-11-16 | Akouos Inc | Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano |
AU2021244559A1 (en) | 2020-03-24 | 2022-11-17 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics |
JP2023520764A (ja) | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | 第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用 |
WO2021202494A1 (en) | 2020-03-31 | 2021-10-07 | University Of Massachusetts | Aav capsids variants and uses thereof |
EP4150626A1 (en) | 2020-04-29 | 2023-03-22 | The Broad Institute Inc. | Machine learning accelerated protein engineering through fitness prediction |
AU2021275239A1 (en) | 2020-05-21 | 2022-12-15 | Board Of Regents, The University Of Texas System | T cell receptors with VGLL1 specificity and uses thereof |
CN116406305A (zh) | 2020-08-17 | 2023-07-07 | 麻省理工学院 | Shank3基因治疗方法 |
WO2022079664A1 (en) | 2020-10-15 | 2022-04-21 | Bausch & Lomb Ireland Limited | Benzalkonium chloride for use in treating conjunctivitis and/or covid-19 |
WO2022120080A1 (en) | 2020-12-03 | 2022-06-09 | University Of Massachusetts | Development of novel gene therapeutics for fibrodysplasia ossificans progressiva |
MX2023011004A (es) | 2021-03-19 | 2024-01-08 | Trained Therapeutix Discovery Inc | Compuestos para regular la inmunidad entrenada y métodos para usarlos. |
MX2023012643A (es) | 2021-04-27 | 2024-01-05 | Generation Bio Co | Vectores de adn no virales que expresan anticuerpos terapéuticos y usos de estos. |
EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
CA3217972A1 (en) | 2021-05-10 | 2022-11-17 | Haitham AMAL | Pharmaceutical compositions for treating neurological conditions |
AU2022356427A1 (en) | 2021-09-30 | 2024-05-09 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
WO2023164545A1 (en) | 2022-02-23 | 2023-08-31 | Massachusetts Institute Of Technology | Methods for upregulating shank3 expression |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024105638A1 (en) | 2022-11-18 | 2024-05-23 | Jcr Pharmaceuticals Co., Ltd. | Recombinant aav vectors and methods for treatment of hunter syndrome |
WO2024168010A2 (en) | 2023-02-09 | 2024-08-15 | Alnylam Pharmaceuticals, Inc. | Reversir molecules and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02273539A (ja) * | 1989-04-14 | 1990-11-08 | Fuji Photo Film Co Ltd | リポソームの保存方法 |
JPH0361859A (ja) * | 1989-07-31 | 1991-03-18 | Nitsusui Seiyaku Kk | リポソーム分散液安定化剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL79114A (en) * | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
US4818537A (en) * | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
JPH0374323A (ja) * | 1989-08-14 | 1991-03-28 | Fuji Photo Film Co Ltd | リポソームの保存方法 |
US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
JP3360325B2 (ja) * | 1991-11-21 | 2002-12-24 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2501730B2 (ja) | 1992-09-22 | 1996-05-29 | サンキン株式会社 | 温室用シ―トの張設部材 |
-
1991
- 1991-05-27 JP JP22376191A patent/JP3218637B2/ja not_active Expired - Fee Related
-
1992
- 1992-04-21 WO PCT/JP1992/000512 patent/WO1993020934A1/ja not_active Application Discontinuation
- 1992-04-21 EP EP92908351A patent/EP0637463A4/en not_active Ceased
- 1992-04-21 CA CA002118487A patent/CA2118487A1/en not_active Abandoned
- 1992-04-21 US US08/318,750 patent/US5565213A/en not_active Expired - Fee Related
- 1992-04-21 KR KR1019940703704A patent/KR950701248A/ko not_active Application Discontinuation
- 1992-04-21 AU AU15488/92A patent/AU672579B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02273539A (ja) * | 1989-04-14 | 1990-11-08 | Fuji Photo Film Co Ltd | リポソームの保存方法 |
JPH0361859A (ja) * | 1989-07-31 | 1991-03-18 | Nitsusui Seiyaku Kk | リポソーム分散液安定化剤 |
Also Published As
Publication number | Publication date |
---|---|
JP3218637B2 (ja) | 2001-10-15 |
JPH054037A (ja) | 1993-01-14 |
AU1548892A (en) | 1993-11-18 |
EP0637463A1 (en) | 1995-02-08 |
KR950701248A (ko) | 1995-03-23 |
AU672579B2 (en) | 1996-10-10 |
US5565213A (en) | 1996-10-15 |
EP0637463A4 (en) | 1996-07-03 |
CA2118487A1 (en) | 1993-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993020934A1 (fr) | Suspension aqueuse stable contenant des liposomes | |
DE69425773T2 (de) | Stabile wässrige liposomenhaltige Dispersionen | |
CA1330532C (en) | Manufacturing unilamellar lipid vesicles | |
US5152923A (en) | Process for the production of a nanoemulsion of oil particles in an aqueous phase | |
US5962015A (en) | Stabilized liposomes | |
Aboofazeli et al. | Investigations into the formation and characterization of phospholipid microemulsions. IV. Pseudo-ternary phase diagrams of systems containing water-lecithin-alcohol and oil; the influence of oil | |
EP0243446B1 (en) | Alpha tocopherol-based vesicles | |
US5035895A (en) | Emulsified and solubilized pharmaceutical preparation | |
AU702366B2 (en) | Microemulsions for use as vehicles for administration of active compounds | |
US5206219A (en) | Oral compositions of proteinaceous medicaments | |
ZA200209520B (en) | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds. | |
US4649155A (en) | Injectable solutions | |
DE3207480A1 (de) | Praeparat mit ausgezeichneten absorptionseigenschaften | |
JP2000086501A (ja) | ヒトカルシトニンのリポソーム製剤 | |
CA1206093A (en) | Gelatin based synthetic whole blood and a process for preparing the same | |
JP5588619B2 (ja) | pH応答性リポソーム | |
JP2807840B2 (ja) | リポソーム及びリン脂質分散液の安定化法 | |
JPH06336442A (ja) | 安定なリポソーム水分散液 | |
JP3072340B2 (ja) | 水性目薬及びその製造法 | |
JP2627158B2 (ja) | 脂溶性物質の安定な水溶液 | |
van Duck et al. | [4] Bacteriorhodopsin in phospholipid vesicles | |
JP2010235491A (ja) | 化粧料用リポソーム | |
JPH06321772A (ja) | 水性リポソーム系およびそのリポソーム系の調製法 | |
JP2006124378A (ja) | 化粧料用リポソーム | |
JPH04270218A (ja) | ビタミンa含有リポソーム水懸濁液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992908351 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2118487 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08318750 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992908351 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1992908351 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992908351 Country of ref document: EP |